1. XBP1 increases transactivation of somatic mutants of ESR1 and loss of XBP1 reverses endocrine resistance conferred by gain-of-function Y537S ESR1 mutation
- Author
-
Ananya Gupta, David Barua, Benazir Abbasi, and Sanjeev Gupta
- Subjects
0301 basic medicine ,Cell biology ,XBP1 ,Molecular biology ,Mutant ,Estrogen receptor ,ESR1 mutations ,Cancer research ,Biology ,Biochemistry ,Fusion gene ,03 medical and health sciences ,Transactivation ,0302 clinical medicine ,lcsh:Social sciences (General) ,lcsh:Science (General) ,Transcriptomics ,Transcription factor ,Multidisciplinary ,Point mutation ,body regions ,030104 developmental biology ,ER-Positive breast cancer ,lcsh:H1-99 ,Estrogen receptor alpha ,030217 neurology & neurosurgery ,lcsh:Q1-390 ,Research Article ,Endocrine resistance - Abstract
Somatic mutations of the estrogen receptor 1 gene (ESR1) is an emerging mechanism of acquired resistance to endocrine therapy in hormonal breast cancers. Hotspot point mutations in the ligand- binding domain of estrogen receptor α (ER) and genomic rearrangements producing ESR1 fusion genes are the two major types of mutations that are associated with endocrine resistance. The crosstalk between X-box binding protein 1 (XBP1), a key transcription factor of the unfolded protein response (UPR) and ER signalling creates a positive feedback loop that results in increased expression of XBP1 in ER-positive breast cancer. Here we report that XBP1 co-operated with point mutants (Y537S, D538G) and fusion mutants (ESR1-YAP1, ESR1-DAB2) of ESR1 to increase their transcriptional activity. XBP1 was required for optimal expression of estrogen-regulated genes, and up to 40% of XBP1-dependent genes were estrogen-responsive genes. Knockdown of XBP1 in genome-edited MCF7 cells expressing Y537S mutant reduced their growth, re-sensitized them to anti-estrogens and attenuated the constitutive and estrogen-stimulated expression of estrogen-regulated genes. Our study provides a rationale for overcoming endocrine resistance in breast cancers expressing ESR1 mutation by combining the XBP1 targeting agents with anti-estrogen agents., Cell biology; Transcriptomics; Biochemistry; Molecular biology; Cancer research; ESR1 mutations, Endocrine resistance, XBP1, ER-Positive breast cancer
- Published
- 2020